Kinetic studies on aminopeptidase M-mediated degradation of human hemorphin LVV-H7 and its N-terminally truncated products

Journal of Peptide Science

Volumn 14, Issue 7, 2008, Pages 797-803

  John, Harald ^a,c   John, Stefanie ^a   Forssmann, Wolf Georg ^b  

^a IPF PHARMACEUTICALS GMBH   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

Author keywords

Aminopeptidase M; CZE; Enzyme kinetics; Hemorphin; IRAP; LVV H7

Indexed keywords

HEMORPHIN 7; MICROSOMAL AMINOPEPTIDASE; TETRAPEPTIDE;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CAPILLARY ZONE ELECTROPHORESIS; DEGRADATION KINETICS; ENZYMATIC DEGRADATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME KINETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS;

AMINO ACID SEQUENCE; ANTIGENS, CD13; HEMOGLOBINS; HUMANS; KINETICS; PEPTIDE FRAGMENTS; SUBSTRATE SPECIFICITY;

SUS;

EID: 48249107458     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1002     Document Type: Article

References (38)

1. Fruitier I, Garreau I, Piot JM. Cathepsin D is a good candidate for the specific release of a stable hemorphin from hemoglobin in vivo: VV-hemorphin-7. Biochem. Biophys. Res. Common. 1998; 246: 719-724.
2. Sanderson Nydahl K, Pierson J, Nyberg F, Caprioli RM, Andren PE. In vivo processing of LVV-hemorphin-7 in rat brain arid blood utilizing microdialysis combined with electrospray mass spectrometry. Rapid Commun. Mass Spectrom. 2003; 17: 838-844.
3. Jinsmaa Y, Yoshikawa M. Release of hemorphin-5 from human hemoglobin by pancreatic elastase. Biosci. Biotechnol. Biochem. 2002; 66: 1130-1132.
4. Fruitier I, Garreau I, Lacroix A, Cupo A, Piot JM. Proteolytic degradation of hemoglobin by endogenous lysosomal proteases give rise to bioactive peptides: hemorphins. FEBS Lett. 1999; 447: 81-86.
5. 4) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 2001; 276: 48623-48626.
6. Cejka J, Zelezna B, Velek J, Zicha J, Kunes J. LVV-hemorphin-7 lowers blood pressure in spontaneously hypertensive rats: radiotelemetry study. Physiol. Res. 2004; 53: 603-607.
7. Nyberg F, Sanderson K, Glämsta EL. The hemorphins: a new class of opioid peptides derived from the blood protein haemoglobin. Biopoly 1997; 43: 147-156.
8. Albiston AL, Pederson ES, Burns P, Purcell B, Wright JW, Harding JW, Mendelsohn FA, Weisinger RS, Chai SY. Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms. Behav. Brain Res. 2004; 154: 239-243.
9. Albiston AL, Fernando R, Ye S, Peck GR, Chai SY. Alzheimer's, angiotensin IV and an aminopeptidase. Boil. Pharm. Bull. 2004; 27: 765-767.
10. Lammerich HP, Busmann A, Kutzleb Ch, Wendland M, Seiler P, Berger C, Eickelmann P, Meyer M, Forssmann WG, Maronde E. Identification and functional characterization of hemorphins VV-H7 and LVV-H-7 as low-affinity agonists for the orphan bombesin receptor subtype 3. Br. J. Pharmacol. 2003; 138: 1431-1440.
11. Fernando RN, Luff SE, Albiston AL, Chai SY. Sub-cellular localization of insulin-regulated membrane aminopeptidase, IRAP to vesicles in neurons. J. Neurochem. 2007; 102: 967-976.
12. Ye S, Chai SY, Lew RA, Albiston AL. insulin-regulated aminopeptidase: analysis of peptide substrate and inhibitor binding to the catalytic domain. Biol. Chem. 2007; 388: 399-403.
13. Hayakari M, Satoh K, Izumi H, Kudoh T, Asano J. Yamazaki T, Tsuchida S. Kinetic-controlled hydrolysis of Leu-Val-Val-hemorphin-7 catalyzed by angiotensin-converting enzyme from rat brain. Peptides 2003; 24: 1075-1082.
14. Murillo L, Piot JM, Coitoux C, Fruitier-Arnaudin I. Brain processing of hemorphin-7 peptides in various subcellular fractions from rats. Peptides 2006; 27: 3331-3340.
15. Sanderson K, Andren PE, Caprioli RM, Nyberg F. In vitro metabolism of LVV-hemorphin-7 in human plasma studied by reversed-phase high-performance liquid chromatography and micro-electrospray mass spectrometry. J. Chromatogr. A 1996; 743: 207-212.
16. John H, Schulz S, Forssmann WG. Comparative in vitro degradation of the human hemorphin LVV-H7 in mammalian plasma analysed by capillary zone electrophoresis and mass spectrometry. Biopharm. Drug Dispos. 2007; 28: 73-85.
17. Lendeckel U, Kähne T, Arndt M, Frank K, Ansorge S. Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299. Biochem. Biophys. Res, Commun. 1998; 252: 5-9.
18. van Hensbergen Y, Broxterman HJ, Hanemaaijer R, Jorna AS, van Lent NA, Verheul HMW, Pinedo HM, Hoekman K. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid. Clin. Cancer Res. 2002; 8: 3747-3754.
19. Saito M, Aoyaki T, Umezawa H, Nagai Y. Bestatin, a new specific inhibitor of aminopeptidases, enhances activation of small lymphocytes by concanavalin A. Biochem. Biophys. Res. Commun. 1977; 76: 526-533.
20. Noren K, Hansen GH, Clausen HH, Noren O, Sjöström H, Vogel LK. Defectively N-glycosylated and non-O-glycosylated aminopeptidase N (CD13) is normally expressed at the cell surface and has full enzymatic activity. Exp. Cell Res. 1997; 231: 112-118.
21. Xu Y, Lai LT, Gabrilove JL, Scheinberg DA. Antitumor activity of actinonin in vitro and in vivo. Clin. Cancer Res. 1998; 4: 171-176.
22. Tokioka-Terao M, Hiwada K, Kokubu T. Purification and characterization of aminopeptidase N from human plasma. Enzyme 1984; 32: 65-75.
23. Favaloro EJ, Browning T, Facey D. CD13 (GP150; aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp. Hematol. 1993; 21: 1695-1701.
24. John H, Huynh KD, Hedtmann Ch, Walden M, Schulz A, Anspach FB, Forssmann WG. In vitro degradation of the antimicrobial human peptide HEM-γ 130-146 in plasma analyzed by a validated quantitative LC-MS/MS procedure. Anal. Biochem. 2005; 341: 173-186.
25. Balogh A, Cadel S, Foulon T, Picart R, Der Garabedian A, Rousselet A, Tougard C, Cohen P. Aminopeptidase B: a processing enzyme secreted and associated with the plasma membrane of rat pheochromocytoma (PC12) cells. J. Cell Sci. 1998; 111: 161-169.
26. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashum RA, Shapiro LH, Arap W, Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000; 60: 722-727.
27. John H, Schulz S, Forssmann WG. Validated multi-component CZE-UV procedure for the quantification of human hemorphin LVV-H7 in plasma stability studies. Anal. Bioanal. Chem. 2006; 386: 235-243.
28. Safavi A, Hersh LB. Degradation of dynorphin-related peptides by the puromycin-sensitive aminopeptidase and aminopeptidase M. J. Neurochem. 1995; 65: 389-395.
29. Huang X, Miller W. A time-efficient, linear-space local similarity algorithm. Adv. Appl. Math. 1991; 12: 337-357.
30. Murray H, Turner AJ, Kenny AJ. The aminopeptidase activity in the human T-cell lymphoma line (Jurkat) is not at the cell surface and is not aminopeptidase N (CD-13). Biochem. J. 1994; 298: 353-360.
31. Lee HS, Kim YJ, Bae SS, Jeon JH, Lim JK, Jeong BC, Kang SG, Lee JH. Cloning, expression, and characterization of aminopeptidase P from the hyperthermophilic archaeon Thermococcus sp. Strain NA1. Appl. Environ. Microbiol. 2006; 72: 1886-1890.
32. 5-enkephalin aminopeptidase hydrolysis by various endogenous peptides and a select number of clinically used drugs. Am. J. Ther. 2004; 11: 459-465.
33. Kramer W, Girbig F, Corsiero D, Pfenninger A, Frick W, Jähne G, Rhein M, Wendler W, Lottspeich F, Hochleitner EO, Orso E, Schmitz G. Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 2005; 280: 1306-1320.
34. Garreau I, Chansel D, Vandermeersch S, Fruitier I, Piot JM, Ardaillou R. Hemorphins inhibit angiotensin IV binding and interact with aminopeptidase N. Peptides 1998; 19: 1339-1348.
35. Cardillo G, Gentilucci L, Tolomelli A, Calienni M, Qasem AR, Spampinato S. Stability against enzymatic hydrolysis of endomorphin-1 analogues containing β-proline. Org. Biomol. Chem. 2003; 1: 1498-1502.
36. Bawab W, Querido E, Crine P, DesGroseillers L. Identification and characterization of aminopeptidases from Aplysia californica. Biochem. J. 1992; 286: 967-975.
37. Terashima H, Bunnett NW. Purification and characterization of aminopeptidase M from muscle and mucosa of the pig intestine. J. Gastroenterol. 1995; 30: 696-704.
38. Bausback HH, Ward PE. Degradation of low-molecular-weight opioid peptides by vascular plasma membrane aminopeptidase M. Biochim. Biophys. Acta 1986: 882: 437-444.